Las Vegas Sun

Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types

Incyte (Nasdaq: INCY) today announced complete safety and efficacy data from all patients (n=16) enrolled in the Phase 1/2 multidose study of VGA039 (latarcibart), a novel, Protein S-targeting, ...
Rutland Herald

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for ...

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug ...

PMET Demonstrates >97% Caesium Extraction from Pollucite Concentrate

Multiple pathways to value-add caesium chemicals identified during bench-scale extraction testwork at SGS Lakefield and ...
The Manila Times

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...
The Manila Times

AIM ImmunoTech Announces Release of New CEO Corner Segment Highlighting Growing Momentum Across Pancreatic Cancer Program

CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer ...
Kauppalehti

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, ...
Rutland Herald

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement ...
Las Vegas Sun

Vertex to Acquire Crinetics Pharmaceuticals

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of ...

Opus Genetics, Inc.: Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results

Opus Genetics, Inc. (Nasdaq: IRD) (the "Company", "Opus Genetics" or "Opus"), a clinical-stage biopharmaceutical company developing gene ...

‘Only women (cis or trans)’: University of Melbourne’s $200,000 lecturer role

The University of Melbourne is seeking a new senior lecturer in mathematical physics — but only women (cis or trans) need ...

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx to receive up to $375 million in non-dilutive cash and up to $25 million in equity investmentFollowing regulatory approval, Oberland Capital to receive low single-digit capped royalties on th ...

Butler National Corporation (BUKS) Q4 2026 Earnings Call Transcript

Today is Wednesday, July 8, and welcome to the Butler National Corporation Conference Call. [Operator Instructions] Your call leaders for today's call are Jeffrey D. Yowell, Executive Chairman; Adam ...